Milestone Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications.. The company’s lead product investigational candidate, etripamil (MSP-2017), is entering Phase 3 development. Etripamil is a new, potent, short-acting, investigational calcium channel blocker being developed as a rapid-onset nasal spray that can be self-administered to terminate paroxysmal supraventricular tachycardia (PSVT) episodes.
Featured News & Events
Milestone Pharmaceuticals Appoints Paul Edick Chairman of its Board of Directors
Milestone Pharmaceuticals today announced the appointment of Paul Edick as Chairman of its Board of Directors. Mr. Edick currently serves as Chairman and Chief Executive Officer of Xeris Pharmaceuticals.